ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.03 -0.29 (-6.71%)
At close: Oct 23, 2026 · 4:00 PM EDT

ARS Pharmaceuticals (SPRY) Return on Sales [ROS] (2020 - 2026)

Updated

ARS Pharmaceuticals (SPRY) posted Return on Sales [ROS] of -182.62% for Q2 2026, up 120.33 percentage points from -302.95% a year earlier and up 82.56 percentage points from the prior quarter.

Analysis

ARS Pharmaceuticals (SPRY) Return on Sales [ROS] (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at ARS Pharmaceuticals was -184.96%, down 132.13 percentage points year-over-year; for FY2025, it came in at -212.92%, down 209.47 percentage points from FY2024.

  • Annual Return on Sales [ROS] shows a four-year change of +140.40 percentage points (FY2021 to FY2025).
  • In prior years, ARS Pharmaceuticals' Return on Sales [ROS] was -3.46% in FY2024 (+225063.21 pp), -225066.67% in FY2023 (-222367.88 pp), -2698.78% in FY2022 (-2345.46 pp) and -353.32% in FY2021.
  • Quarterly Return on Sales [ROS] has run from a low of -619990.00% in Q1 2024 to a high of 54.51% in Q4 2024 over five years.
  • On a year-over-year basis, Return on Sales [ROS] increased in seven of the last eight quarters, with an average year-over-year change of +136227.78 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q1 2025, with a gain of 619523.71 percentage points; the weakest was Q1 2024, with a drop of 526425.00 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -265.18% (Q1 2026), -147.63% (Q4 2025) and -163.66% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 ARS Pharmaceuticals 400.73 Mn 256.93 Mn 20.81 Mn -182.62%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -182.62%
Mar 31, 2026 -265.18%
Dec 31, 2025 -147.63%
Sep 30, 2025 -163.66%
Jun 30, 2025 -302.95%
Mar 31, 2025 -466.29%
Dec 31, 2024 54.51%
Sep 30, 2024 -1,051.64%
Jun 30, 2024 -3,068.00%
Mar 31, 2024 -619,990.00%
Dec 31, 2023 -225,066.67%
Sep 30, 2023 -242,456.67%
Jun 30, 2023 -206,030.00%
Mar 31, 2023 -93,565.00%
Dec 31, 2022 -2,698.78%
Sep 30, 2022 -3,507.94%
Jun 30, 2022 -1,367.24%
Mar 31, 2022 -1,070.74%
Dec 31, 2021 99,197.87%
Sep 30, 2021 -87,234.62%
API Access

ARS Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=SPRY&period=max&api_key=YOUR_API_KEY